Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.

Also called NCT03284827

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 235 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03284827
Other papers using this trial's data
  • Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial Circulation, 2022-08-09 DOI, PubMed 35373583
  • Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement Heart (British Cardiac Society), 2023-12-20 DOI, PubMed 37586823

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Hong Kong SAR China, South Korea, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03284827. Randomized; no masking; primary purpose prevention. Start 2018-03-15 (actual); primary completion 2021-10-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
Acronym
ADAPT-TAVR
Condition
Aortic Valve Stenosis
Intervention (Drug)
NOAC
Intervention (Drug)
DAPT
Lead sponsor
Duk-Woo Park, MD (class: other)
Collaborator
CardioVascular Research Foundation, Korea (class: other)
Collaborator
Daiichi Sankyo Korea Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03284827
Content hash
baf2ef8576a9c0e28533718c9ce8781d40df2057a45151a93a6ab1d5a4c21261